Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 2
1992 3
1993 2
1994 1
1995 2
1996 2
1997 2
1998 2
1999 2
2000 1
2001 4
2002 1
2003 3
2004 8
2005 6
2006 5
2007 6
2008 1
2009 2
2010 3
2011 6
2012 4
2013 6
2014 5
2015 6
2016 2
2017 4
2018 1
2019 9
2020 9
2021 9
2022 11
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. Among authors: rapoport ap. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Nastoupil LJ, et al. Among authors: rapoport ap. J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13. J Clin Oncol. 2020. PMID: 32401634 Free PMC article.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. Rapoport AP, et al. Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193344 Free PMC article.
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Holtzman NG, et al. Among authors: rapoport ap. Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183. Neuro Oncol. 2021. PMID: 32750704 Free PMC article. Review.
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Jain MD, Dahiya S, Locke FL, Miklos DB. Frank MJ, et al. Among authors: rapoport ap. J Clin Oncol. 2021 Sep 20;39(27):3034-3043. doi: 10.1200/JCO.21.00377. Epub 2021 Jun 16. J Clin Oncol. 2021. PMID: 34133196 Free PMC article.
Check(point) or checkmate for acute myeloid leukemia?
Niyongere S, Rapoport AP. Niyongere S, et al. Among authors: rapoport ap. Haematologica. 2021 May 1;106(5):1230-1231. doi: 10.3324/haematol.2020.277103. Haematologica. 2021. PMID: 33538155 Free PMC article. No abstract available.
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Wang Y, et al. Among authors: rapoport ap. J Clin Oncol. 2023 May 10;41(14):2594-2606. doi: 10.1200/JCO.22.01797. Epub 2023 Feb 8. J Clin Oncol. 2023. PMID: 36753699
Lenalidomide-induced eosinophilic pneumonia.
Toma A, Rapoport AP, Burke A, Sachdeva A. Toma A, et al. Among authors: rapoport ap. Respirol Case Rep. 2017 Apr 25;5(4):e00233. doi: 10.1002/rcr2.233. eCollection 2017 Jul. Respirol Case Rep. 2017. PMID: 28451433 Free PMC article.
Donating used CARs.
Rapoport AP. Rapoport AP. Blood. 2013 Dec 12;122(25):4007-9. doi: 10.1182/blood-2013-10-528984. Blood. 2013. PMID: 24335030 Free article.
Hemopoietic growth factors: a review.
Rowe JM, Rapoport AP. Rowe JM, et al. Among authors: rapoport ap. J Clin Pharmacol. 1992 Jun;32(6):486-501. doi: 10.1177/009127009203200602. J Clin Pharmacol. 1992. PMID: 1378857 Review.
127 results